Achmea Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,841
| Closed | -$1.31M | – | 395 |
|
|
2024
Q4 | $1.31M | Sell |
1,841
-17,567
| -91% | -$14.7M | 0.02% | 324 |
|
|
2024
Q3 | $20.4M | Buy |
19,408
+2,521
| +15% | +$2.81M | 0.34% | 76 |
|
|
2024
Q2 | $17.7M | Buy |
16,887
+272
| +2% | +$264K | 0.32% | 77 |
|
|
2024
Q1 | $16M | Buy |
16,615
+4,612
| +38% | +$4.39M | 0.3% | 83 |
|
|
2023
Q4 | $10.5M | Sell |
12,003
-2,732
| -19% | -$2.25M | 0.22% | 113 |
|
|
2023
Q3 | $12.1M | Sell |
14,735
-2,393
| -14% | -$1.88M | 0.26% | 96 |
|
|
2023
Q2 | $12.3M | Buy |
17,128
+2,610
| +18% | +$2.01M | 0.26% | 97 |
|
|
2023
Q1 | $11.9M | Sell |
14,518
-6,204
| -30% | -$4.68M | 0.35% | 73 |
|
|
2022
Q4 | $14M | Sell |
20,722
-1,359
| -6% | -$1M | 0.47% | 47 |
|
|
2022
Q3 | $15.2M | Sell |
22,081
-4,711
| -18% | -$2.97M | 0.54% | 37 |
|
|
2022
Q2 | $15.8M | Buy |
26,792
+1,871
| +8% | +$1.22M | 0.51% | 37 |
|
|
2022
Q1 | $17.4M | Buy |
+24,921
| New | +$15.8M | 0.45% | 42 |
|
|
2021
Q4 | – | Sell |
-15,197
| Closed | -$9.2M | – | 517 |
|
|
2021
Q3 | $9.2M | Sell |
15,197
-2,612
| -15% | -$1.62M | 0.28% | 99 |
|
|
2021
Q2 | $9.95M | Sell |
17,809
-2,889
| -14% | -$1.46M | 0.34% | 70 |
|
|
2021
Q1 | $9.79M | Sell |
20,698
-500
| -2% | -$243K | 0.34% | 72 |
|
|
2020
Q4 | $10.2M | Buy |
21,198
+5,642
| +36% | +$3.05M | 0.37% | 56 |
|
|
2020
Q3 | $8.71M | Sell |
15,556
-12,932
| -45% | -$7.84M | 0.36% | 71 |
|
|
2020
Q2 | $17.8M | Buy |
+28,488
| New | +$16.2M | 0.6% | 39 |
|
|
2020
Q1 | – | Sell |
-5,903
| Closed | -$2.22M | – | 488 |
|
|
2019
Q4 | $2.22M | Hold |
5,903
| – | – | 0.09% | 237 |
|
|
2019
Q3 | $1.64M | Sell |
5,903
-1,654
| -22% | -$489K | 0.06% | 287 |
|
|
2019
Q2 | $2.36M | Sell |
7,557
-281
| -4% | -$93.5K | 0.09% | 247 |
|
|
2019
Q1 | $3.22M | Buy |
7,838
+3,377
| +76% | +$1.39M | 0.13% | 169 |
|
|
2018
Q4 | $1.67M | Buy |
4,461
+4,132
| +1,256% | +$1.51M | 0.08% | 254 |
|
|
2018
Q3 | $132K | Sell |
329
-564
| -63% | -$215K | 0.01% | 475 |
|
|
2018
Q2 | $308K | Hold |
893
| – | – | 0.01% | 476 |
|
|
2018
Q1 | $307K | Hold |
893
| – | – | 0.01% | 474 |
|
|
2017
Q4 | $335K | Hold |
893
| – | – | 0.01% | 474 |
|
|
2017
Q3 | $399K | Hold |
893
| – | – | 0.02% | 420 |
|
|
2017
Q2 | $438K | Sell |
893
-222
| -20% | -$97.1K | 0.03% | 422 |
|
|
2017
Q1 | $432K | Buy |
+1,115
| New | +$413K | 0.02% | 444 |
|
Other funds holding REGN
Achmea Investment Management's REGN Position: Q1 2025 in Review
Achmea Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 1,841 shares — an estimated $1.31M sold.
Achmea Investment Management first reported a position in REGN in Q1 2017 and held it in 30 quarters. The position peaked at $20.4M in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.
- Achmea Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Achmea Investment Management sold 1,841 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $1.31M.
- Achmea Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 30 quarters.
- Achmea Investment Management's Regeneron Pharmaceuticals position peaked at $20.4M in Q3 2024.
- 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.
Based on Achmea Investment Management's 13F filing for Q1 2025, filed 24 Apr 2025.